Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07360301 · ClinicalTrials.gov registry record · Phase 1
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT07360301 is a Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 120 participants.
The verdict
NCT07360301, a Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.
Interventions
- DRUG Psilocybin
- OTHER Saline Placebo
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-09 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07360301
The ClinicalTrials.gov registry entry for NCT07360301 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Psilocybin is the first listed.
NCT07360301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07360301 about?
NCT07360301 is a clinical study titled "Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study". This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from dir...
What is the current status of trial NCT07360301?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2026-09. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07360301?
The interventions under investigation include: Psilocybin (DRUG), Saline Placebo (OTHER), Clonidine (DRUG).
Who is sponsoring clinical trial NCT07360301?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.